Sandoz Canada announces launch of Jubbonti, Wyost

Sandoz Canada announces the launch of two denosumab biosimilars: Jubbonti and Wyost. Jubbonti is available in 60 mg/mL solution in single-use prefilled syringe and is approved for treating osteoporosis and increasing bone mass. The product is expected to be listed on all provincial formularies in the near future. Wyost is available in 120 mg/1.7 mL solution for subcutaneous injection and is approved for the prevention of bone fractures in bone metastatic cancers and the treatment of bone giant cells tumors in adults. Both internal and external packaging include GS1 standard barcoding for easy identification. Jubbonti is approved for all indications of its reference medicine Prolia while Wyost is approved for all indications of its reference medicine Xgeva.